Xencor Presentations
- Phase 1 study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients; Orlando, FL, June 1st, 2009 (CD30)
- XmAb®5574: an Fc-Engineered Anti-CD19 Monoclonal Antibody with In Vitro and In Vivo Efficacy against Lymphoma and Leukemia; Chicago, IL, June 1st, 2008 (CD19)
- American Association for Cancer Research (AACR) Annual Meeting; San Diego, April 12-16, 2008 (CD19)
- American Society of Hematology 49th Annual Meeting and Exposition; Atlanta, GA, December 8-11, 2007 (CD30)
- IBC Life Sciences' 17th Annual Antibody Engineering Conference; San Diego, December 2-6, 2007 (CD19)
- 7th International Symposium on Hodgkin Lymphoma; Cologne, Germany, November 3-7, 2007 (CD30)
- Life Sciences 2007; Glasgow, UK, July 8-12, 2007 (Fc)
- American Association for Cancer Research (AACR) Annual Meeting; Los Angeles, April 14-18, 2007 (Fc)
- American Association for Cancer Research (AACR) Annual Meeting; Los Angeles, April 14-18, 2007 (CD19)
- American College of Rheumatology (ACR): Innovative Therapies in Autoimmune Diseases; Arlington, VA, March 2-4, 2007
- IBC Protein Engineering for Biotherapeutics Conference; San Diego, December 12-14, 2006 (Fc)
- IBC Protein Engineering for Biotherapeutics Conference; San Diego, December 12-14, 2006 (ImmunoFilter technology)
- American Society of Hematology (ASH) Annual Meeting 2005; Atlanta, GA; December 10-13, 2005
